The production of reactive oxygen species (ROS) and oxidative stress are central to the pathophysiology of diabetic wounds. This environment arises from the interplay of hyperglycemia, mitochondrial dysfunction, and chronic inflammation, leading to persistent damage. This hypothesis paper explores the therapeutic potential of Platelet-Rich Plasma (PRP) for accelerating diabetic wound healing. We specifically focus on PRP’s ability to modulate ROS and the key processes of Epithelial/Endothelial-to-Mesenchymal Transition (EMT/EndMT). PRP, rich in growth factors and functional platelet-derived mitochondria, shows promise in treating diabetic wounds by reducing oxidative stress and enhancing cellular processes crucial for healing. We propose that PRP accelerates healing through several interconnected mechanisms: (1) Reducing ROS production and alleviating oxidative stress; (2) Enhancing cell proliferation, migration, and angiogenesis; (3) Transferring healthy platelet-derived mitochondria to replace damaged host cell mitochondria, restoring energy metabolism; (4) Modulating cellular signaling pathways regulating ROS generation and scavenging systems, and subsequently impacts EMT/EndMT processes; and (5) Directly modulating EMT/EndMT dynamics. This hypothesis examines these proposed mechanisms and highlights future research priorities necessary to elucidate PRP’s precise mode of action and refine its clinical applications for diabetic wounds. Furthermore, the potential of PRP in treating other oxidative stress-related conditions warrants investigation.
Iatrogenic wounds are a common but often overlooked concept. They can lead to increases in hospital stays, therapy costs, repeat surgeries, and implant removal. If not handled properly, these wounds have a very poor prognosis and will cause serious physical and psychological harm to patients, which may result in medicolegal disputes. In recent years, the incidence of iatrogenic wounds has increased because of (1) an increase in the population of older people owing to increased life expectancy, (2) the continued expansion of surgical indications, (3) an increase in difficult surgeries, and (4) the constant emergence and application of new implantable biomaterials and other therapies. Thus, there is a pressing clinical need to improve the therapy of iatrogenic wounds. However, the difficulty in treating these wounds is considerable due to the emergence of drug-resistant bacteria, the high number of patients with metabolic diseases, and complex complications in patients. In particular, iatrogenic wounds caused by surgical site infections due to implantable biomaterials could lead to material leakage and conflicts regarding whether to retain or remove the implants. This review provides a definition of iatrogenic wounds, describes their characteristics, classifies them, and provides information about the importance of analyzing iatrogenic wounds. We hope that this review will provide useful information for the diagnosis and treatment of iatrogenic wounds and help to reduce their incidence in the future.
7 August 2025 in Frontiers in Bioengineering and Biotechnology
Platelet concentrates (PCs) have evolved from classical formulations to exosome-based therapies, reflecting a paradigm shift in regenerative medicine. This review analyzes three generations of PCs products, comparing their technological progress, functional differences, and clinical applications. It proposes a novel function-driven classification system that redefines PCs generations based on biological activity rather than chronological development. First-generation PCs, such as platelet-rich plasma (PRP) and platelet-rich growth factor plasma (PRGF), employ centrifugation to concentrate platelets but exhibit limited therapeutic duration due to rapid growth factor depletion and absent fibrin matrices. Second-generation PCs, including platelet-rich fibrin (PRF) and concentrated growth factor (CGF), form natural fibrin networks through low-speed centrifugation, facilitating prolonged cytokine release, though their effectiveness depends heavily on cellular viability. Third-generation PCs represent a paradigm shift by harnessing extracellular vesicles, notably platelet-derived exosomes (PLEXOs). These 30–150 nm vesicles carry growth factors, miRNAs, and lipids, mediating targeted intercellular signaling, immune regulation, and regenerative processes. PLEXOs exhibit greater therapeutic efficacy than previous PCs generations in diverse clinical contexts. Our systematic analysis of PCs evolution and underlying molecular mechanisms addresses three key limitations of extracellular vesicle-based therapies: poor isolation efficiency, regulatory ambiguity, and inconsistent treatment protocols. Critical challenges persist in standardizing extracellular vesicle isolation, scaling production, and validating long-term safety. Future solutions may involve engineered extracellular vesicles, genomic editing, and aptamer-functionalized precision theranostics. The proposed “PRP rapid activation → PRF scaffolding → PLEXOs repair” tri-step therapy demonstrates how intergenerational synergies could advance regenerative medicine with enhanced precision and clinical potential.